Cell Therapy Trial Targets Corneal Disease - Takeaways - MDSpire
Clinical Guidelines

Cell Therapy Trial Targets Corneal Disease

Aurion Biotech launches phase 3 trial for corneal endothelial cell therapy

  • May 4, 2026

  • 2 min

Share

  • 1

    AURN001 is in a phase 3 ASTRA trial for corneal endothelial disease.

  • 2

    Focus on efficacy/safety and ≥15-letter improvement in BCVA.

  • 3

    12 U.S. trial sites.

  • 4

    Combines cultured endothelial cells and rho-kinase inhibitor.

  • 5

    Aims to reduce reliance on donor tissue.

  • 6

    Previous success in Japan; seeking U.S. biologics application.

  • 7

    Addresses global visual impairment due to endothelial dysfunction.

Original Source(s)

Cell Therapy Trial Targets Corneal Disease

  • May 4, 2026

Related Content

AI Boosts Diabetic Eye Care Access

Recent study highlights how integrated AI-assisted DR screening in primary care clinics can improve access and decrease disparity

  • May 5, 2026

  • 3 min
Surgical Confidence with Hydrus®

Nishani Amerasinghe shares surgical tips and pearls for the Hydrus® Microstent

  • May 5, 2026

  • 5 min
The Art of Ophthalmology 2026

Showcasing artwork and images from across the spectrum of ophthalmology